Tamiflu® World™

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 2.5 License.

Roche Pharmaceuticals Tamiflu® capsule and packaging

Articles

11-15-05: Gilead and Roche end Tamiflu® dispute (Tamiflu® World #14)

10-27-05: Roche stops shipping Tamiflu® (Tamiflu® World #13)

10-25-05: Tamiflu® counterfeiting and overuse emerge as new issues; FDA Director issues vague warnings against anti-viral self-medication with Tamiflu® (Tamiflu® World #12)

10-24-05: The U.S. patent on oseltamivir, sold under the brand name "Tamiflu®," belongs to Gilead Sciences, Inc., of Foster City, California (Tamiflu® World #11)

10-23-05: "People before profits" mind-set drives multi-faceted onslaught against Roche Pharmaceuticals, patent-holder on Tamiflu® (Tamiflu® World #10)

10-23-05: Gilead Sciences' Director of Public Affairs says that "any potential sub-license is the responsibility of Roche as it pertains to contract manufacturing" of Tamiflu® (Tamiflu® World #9)

10-21-05: Ownership of Tamiflu® in doubt as Senator Schumer forces Roche to license rights to four generic manufacturers, three of which are already at each others' throats (Tamiflu® World #8)

10-17-05: Gilead Sciences, Inc., inventor of Tamiflu®, is seeking to terminate its 1996 agreement with Roche, which would result in the rights to Tamiflu held by Roche reverting to Gilead (Tamiflu® World #7)

10-16-05: Star anise provides shikimic acid to make Tamiflu®; Roche and Michigan State University have developed a way to make it without the plant (Tamiflu® World #6)

10-16-05: Flu Wiki, an online "public health experiment," emerges to facilitate and encourage local responses to a global avian flu pandemic (Tamiflu® World #5)

10-15-05: Latest news about H5N1 resistance to Tamiflu® points to a combined zanamivir/oseltamivir strategy including Relenza (Tamiflu® World #4)

10-14-05: Roche declines to comment, as Indian drug company announces its plans to produce a generic version of Roche's patented anti-viral Tamiflu® (Tamiflu® World #3)

10-14-05: Original developers of Tamiflu and Relenza seek reversion of ownership rights; WHO won't pressure Roche on generics; Montanan urges consideration of equity issues in the comparative availability of Tamiflu (Tamiflu® World #2)

10-12-05: Some recent articles and blog posts about Tamiflu (Tamiflu® World #1/Etopia Media Medical News Network #101)

3-25-05: Roche Pharmaceuticals answers some questions about Tamiflu® (Etopia Media Medical News Network #58)

11-3-04: Dr. Dominick Iacuzio, Medical Director at Roche Pharmaceuticals, explains how anti-virals such as Tamiflu® work and how they can provide a more reliable defense against a possible avian influenza pandemic than a strategy relying on vaccination

 

Join the "Tamiflu® World™" mailing list (unless you're already on another Etopia Media mailing list) web site.

Just send an empty e-mail to tamifluworld-subscribe@yahoogroups.com.

 

Get in the swing of things with additional Etopia Media News Network articles and interviews and Google Alerts

To access additional, recent articles from the Etopia Media News Networks web site, as crawled and cataloged on the Google News web site, click here.

To sign up for Google Alerts whenever a new Etopia Media News Networks article appears on Google News, click here.